Literature DB >> 23786440

MRI biomarkers for evaluation of treatment efficacy in preclinical diabetic retinopathy.

Bruce A Berkowitz1, David Bissig, Oliver Dutczak, Shannon Corbett, Rob North, Robin Roberts.   

Abstract

INTRODUCTION: One sober consequence of the current epidemic of diabetes mellitus is that an increasing number of people world-wide will partially or completely lose their sight to diabetic retinopathy. Clinically, the sight-threatening complications of diabetes are diagnosed and treated based on visible retinal lesions (e.g., dot-blot hemorrhages or retinal neovascularization). However, such anatomical microvascular lesions are slow to respond with treatment. Thus, there remains an urgent need for imaging biomarkers that are abnormal before retinal lesions are visibly apparent and are responsive to treatment. AREAS COVERED: Here, the development of new MRI methods, such as manganese-enhanced MRI, for evaluating early diabetes-evoked retinal pathophysiology, and its usefulness in guiding new treatments for diabetic retinopathy are reviewed. EXPERT OPINION: In diabetic retinopathy, not all important diagnostic and prognostic needs are well served by optical methods. In the absence of gross anatomy changes, critical times when drug intervention is most likely to be successful at reducing vision loss are missed by most light-based methods and thus provide little help in guiding diagnosis and treatment. For example, before clinical symptoms, is there an optimal time to intervene with drug therapy? Is a drug reaching its target? How does one assess optimal drug dose, schedule, and routes? How well do current experimental models mimic the clinical condition? As discussed herein, MRI is as an analytical tool for addressing these unmet needs. Future clinical applications of MRI can be envisioned such as in clinical trials to assess drug treatment efficacy, or as an adjunct approach to refine or clarify a difficult clinical case. New MRI-generated hypotheses about the pathogenesis of diabetic retinopathy and its treatment are discussed. In the coming years, a substantial growth in the development and application of MRI is expected to address relevant question in both the basic sciences and in the clinic.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23786440      PMCID: PMC3912437          DOI: 10.1517/17530059.2013.814639

Source DB:  PubMed          Journal:  Expert Opin Med Diagn        ISSN: 1753-0059


  92 in total

1.  Noninvasive and simultaneous imaging of layer-specific retinal functional adaptation by manganese-enhanced MRI.

Authors:  Bruce A Berkowitz; Robin Roberts; Dennis J Goebel; Hongmei Luan
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-06       Impact factor: 4.799

2.  Defective myogenic response to posture change in retinal vessels of well-controlled type 1 diabetic patients with no retinopathy.

Authors:  Mara Lorenzi; Gilbert T Feke; Linda Pitler; Fatmire Berisha; Julia Kolodjaschna; J Wallace McMeel
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-06-30       Impact factor: 4.799

3.  Retinal hemodynamics in early diabetic macular edema.

Authors:  Kit Guan; Chris Hudson; Tien Wong; Mila Kisilevsky; Ravi K Nrusimhadevara; Wai Ching Lam; Mark Mandelcorn; Robert G Devenyi; John G Flanagan
Journal:  Diabetes       Date:  2006-03       Impact factor: 9.461

4.  [Effect of enalaprilat, an angiotensin converting enzyme inhibitor, on the membrane potential of cultured neuroblastoma-glioma hybrid NG108-15 cells].

Authors:  T Yamasaki; M Kawahara; Y Akiyama; K Moritake; K Enomoto; T Maeno
Journal:  No To Shinkei       Date:  1993-11

5.  ZIP8 is an iron and zinc transporter whose cell-surface expression is up-regulated by cellular iron loading.

Authors:  Chia-Yu Wang; Supak Jenkitkasemwong; Stephanie Duarte; Brian K Sparkman; Ali Shawki; Bryan Mackenzie; Mitchell D Knutson
Journal:  J Biol Chem       Date:  2012-08-16       Impact factor: 5.157

6.  Abnormal panretinal response pattern to carbogen inhalation in experimental retinopathy of prematurity.

Authors:  B A Berkowitz; J S Penn
Journal:  Invest Ophthalmol Vis Sci       Date:  1998-04       Impact factor: 4.799

7.  Enalapril and captopril enhance antioxidant defenses in mouse tissues.

Authors:  E M de Cavanagh; C G Fraga; L Ferder; F Inserra
Journal:  Am J Physiol       Date:  1997-02

8.  Non-uniform distribution of lesions and biochemical abnormalities within the retina of diabetic humans.

Authors:  J Tang; S Mohr; Y-D Du; T S Kern
Journal:  Curr Eye Res       Date:  2003-07       Impact factor: 2.424

9.  Captopril inhibits capillary degeneration in the early stages of diabetic retinopathy.

Authors:  Jin-Zhong Zhang; Xia Xi; Ling Gao; Timothy S Kern
Journal:  Curr Eye Res       Date:  2007-10       Impact factor: 2.424

10.  Effects of captopril and enalaprilat on intracellular Ca2+ content in isolated cardiomyocytes from rats.

Authors:  J Wang; L Zhang; J H Qi; P J Zhang; P J Wei; P K Gu; Z J Jin
Journal:  Zhongguo Yao Li Xue Bao       Date:  1996-05
View more
  12 in total

Review 1.  Emerging risk biomarkers in cardiovascular diseases and disorders.

Authors:  Ravi Kant Upadhyay
Journal:  J Lipids       Date:  2015-04-08

2.  The distribution of Mn2+ in rabbit eyes after topical administration for manganese-enhanced MRI.

Authors:  Shenzhi Liang; Miao Liang; Yu Zhu; Jingliang Cheng; Zitao Yang
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

3.  Systemic Retinaldehyde Treatment Corrects Retinal Oxidative Stress, Rod Dysfunction, and Impaired Visual Performance in Diabetic Mice.

Authors:  Bruce A Berkowitz; Timothy S Kern; David Bissig; Priya Patel; Ankit Bhatia; Vladimir J Kefalov; Robin Roberts
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-10       Impact factor: 4.799

4.  Genetic dissection of horizontal cell inhibitory signaling in mice in complete darkness in vivo.

Authors:  Bruce A Berkowitz; Geoffrey G Murphy; Cheryl Mae Craft; D James Surmeier; Robin Roberts
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-05       Impact factor: 4.799

5.  Development of an MRI biomarker sensitive to tetrameric visual arrestin 1 and its reduction via light-evoked translocation in vivo.

Authors:  Bruce A Berkowitz; Jawan Gorgis; Ankit Patel; Faiza Baameur; Vsevolod V Gurevich; Cheryl M Craft; Vladimir J Kefalov; Robin Roberts
Journal:  FASEB J       Date:  2014-10-28       Impact factor: 5.191

6.  Oxidative stress and light-evoked responses of the posterior segment in a mouse model of diabetic retinopathy.

Authors:  Bruce A Berkowitz; Edmund Michael Grady; Nikita Khetarpal; Akshar Patel; Robin Roberts
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-01-08       Impact factor: 4.799

7.  Measuring In Vivo Free Radical Production by the Outer Retina.

Authors:  Bruce A Berkowitz; Bryce X Bredell; Christopher Davis; Marijana Samardzija; Christian Grimm; Robin Roberts
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-12       Impact factor: 4.799

Review 8.  MRI of rod cell compartment-specific function in disease and treatment in vivo.

Authors:  Bruce A Berkowitz; David Bissig; Robin Roberts
Journal:  Prog Retin Eye Res       Date:  2015-09-04       Impact factor: 21.198

9.  Photobiomodulation Mitigates Diabetes-Induced Retinopathy by Direct and Indirect Mechanisms: Evidence from Intervention Studies in Pigmented Mice.

Authors:  Alexandra Saliba; Yunpeng Du; Haitao Liu; Shyam Patel; Robin Roberts; Bruce A Berkowitz; Timothy S Kern
Journal:  PLoS One       Date:  2015-10-01       Impact factor: 3.240

10.  In Vivo Evaluation of the Visual Pathway in Streptozotocin-Induced Diabetes by Diffusion Tensor MRI and Contrast Enhanced MRI.

Authors:  Swarupa Kancherla; William J Kohler; Yolandi van der Merwe; Kevin C Chan
Journal:  PLoS One       Date:  2016-10-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.